Bristol-Myers Squibb (BMY) Tops Q4 EPS by 5c, Offers FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Bristol-Myers Squibb (BMY) Tops Q4 EPS by 5c, Offers FY Guidance

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020

February 4, 2021 6:59 AM EST

Reports Fourth Quarter Revenues of $11.1 Billion; Full-Year Revenues of $42.5 Billion Posts Fourth Quarter Loss Per Share of $4.45 and Non-GAAP EPS of $1.46; Full-Year Loss Per Share of $3.99 and Non-GAAP EPS of $6.44 Completes Acquisition of MyoKardia, Expanding Leading Cardiovascular Franchise Announces Debt Tender Offer for an Aggregate Purchase Price of Up to $4.0 Billion Delivers Positive Results from POETYK-PSO-2 Evaluating Deucravacritinib (TYK2 inhibitor) for Treatment of Moderate to Severe Plaque Psoriasis Announces Licensing Agreement with The Rockefeller University for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of... More